A fixed-dose combination of a standardized Ginkgo biloba leaf extract and the synthetic derivative Vinpocetine, primarily used as a cerebral vasodilator and neuroprotective agent. It works by improving cerebral blood flow, enhancing neuronal metabolism, and providing antioxidant effects. This combination is widely used in India for managing symptoms associated with cognitive decline and cerebrovascular insufficiency.
Adult: One tablet/capsule of Ginkgo Biloba 60mg + Vinpocetine 10mg, two to three times daily.
Note: Administer with or after meals to minimize potential gastric irritation. Swallow whole with a glass of water. Do not crush or chew. Consistent daily dosing is required for cognitive benefits.
The combination exerts synergistic effects. Ginkgo biloba improves microcirculation and rheology, reduces blood viscosity, and acts as a potent antioxidant and platelet-activating factor (PAF) inhibitor. Vinpocetine selectively enhances cerebral blood flow by inhibiting phosphodiesterase type 1 (PDE1), leading to vasodilation, and improves neuronal glucose and oxygen uptake. Together, they increase perfusion and metabolic efficiency in ischemic brain areas.
Pregnancy: CONTRANDICATED. Ginkgo may have uterotonic effects. Vinpocetine safety not established. Risk Category: Not assigned (Herbal products). Avoid.
Driving: May cause dizziness or drowsiness, especially initially. Patients should not drive or operate machinery until their response is known.
| Warfarin, Acenocoumarol | Increased risk of bleeding due to Ginkgo's antiplatelet effect and possible CYP2C9 interaction. | Major |
| Aspirin, Clopidogrel, NSAIDs (e.g., Ibuprofen) | Additive antiplatelet effect, increased bleeding risk. | Moderate |
| Antiepileptics (e.g., Carbamazepine, Valproate) | Ginkgo may reduce seizure threshold; potential reduced efficacy of antiepileptics. | Moderate |
| Antihypertensives (e.g., Amlodipine) | Additive vasodilatory effect may cause excessive hypotension. | Moderate |
| Omeprazole, Pantoprazole | May alter gastric pH and affect absorption of Ginkgo flavonoids. | Minor |
| Trazodone | Case reports of coma with Ginkgo combination. | Major |
| CYP2C9 Substrates (e.g., Phenytoin) | Ginkgo may induce metabolism, reducing efficacy. | Moderate |
Same composition (Ginkgo Biloba (60mg) + Vinpocetine (10mg)), different brands: